HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.
3/5 보강
TL;DR
Results support further development of HS-20093, with 8.0 mg/kg selected for phase 3 trials, with 8.0 mg/kg established as the maximum tolerated dose.
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
HER2/EGFR in Cancer Research
Peptidase Inhibition and Analysis
Results support further development of HS-20093, with 8.0 mg/kg selected for phase 3 trials, with 8.0 mg/kg established as the maximum tolerated dose.
- 표본수 (n) 65
APA
Jianchun Duan, Yuping Sun, et al. (2026). HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.. Cancer cell, 44(4), 846-857.e3. https://doi.org/10.1016/j.ccell.2026.02.006
MLA
Jianchun Duan, et al.. "HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.." Cancer cell, vol. 44, no. 4, 2026, pp. 846-857.e3.
PMID
41791381 ↗
Abstract 한글 요약
This phase 1a/b study (NCT05276609) evaluated the safety, pharmacokinetics, and efficacy of B7-H3-targeted antibody-drug conjugate HS-20093 (GSK5764227) in 306 patients with previously treated advanced solid tumors. In phase 1a, 12.0 mg/kg was established as the maximum tolerated dose. Among 236 lung cancer patients who received 8.0 or 10.0 mg/kg HS-20093, the most frequent grade ≥3 treatment-related adverse events (AEs) included decreased neutrophil (25.5% vs. 50.5%) and white blood cell counts (19.7% vs. 42.4%), and anemia (16.8% vs. 34.3%), respectively. Treatment-related interstitial lung disease and AEs leading to death occurred in 3.4% and 3.8% of patients, respectively. Among response-evaluable patients, the confirmed objective response rate was 52.3% (95% CI: 39.5, 64.9) for extensive-stage SCLC (ES-SCLC, N = 65) and 22.4% (95% CI: 16.0, 29.8) for non-small cell lung cancer (NSCLC, N = 152) patients, with comparable rates between 8.0 mg/kg and 10.0 mg/kg dose cohorts across both groups. These results support further development of HS-20093, with 8.0 mg/kg selected for phase 3 trials.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Risk-Based Local Radiation Therapy in Oligometastatic Non-small Cell Lung Cancer in the Era of Immunotherapy: A Multicentric Cohort Study.
- Dual role of icaritin in attenuating allograft rejection and exerting antitumor effects in mice.
- Lutein Attenuates Parkinson's Disease Progression by Regulating Mitochondrial Function via the TRIM31/Drp1 Signaling Pathway.
- Establishing a novel mouse model of tacrolimus-induced post-transplant hepatocellular carcinoma pulmonary recurrence for transplant oncology.
- Erratum: GALNT6 suppresses progression of colorectal cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.